A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects with Glioblastoma Multiforme - M12-356

AbbVie B.V.0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年4月29日

研究概览

暂无简介。

•Glioblastoma Multiforme (GBM); 70 or above on Karnofsky Performance Status; adequate bone marrow function, Arm A and Expanded Cohort Arm A: Subjects with newly diagnosed GBM; Arm B: Subject has recurrent GBM measureable criteria per RANO or newly diagnosed GBM and has just completed adjuvant radiation and/or TMZ therapy; Arm C and Expanded Cohorts B and C: (With recurrent GBM) Measurable disease per RANO criteria, and have an interval of at least 12 weeks from the completion of radiation therapy to study entry OR have progression which is clearly outside the radiation field.

•For subjects in Arm A, Arm B and the Expanded Cohort with newly diagnosed GBM: Subject has received prior chemotherapy or radiotherapy for cancer in the head and neck region; Recurrent GBM in Arm B: no prior treatment bevacizumub, nitrosourea, more than 2 therapies, or has secondary GBM; Arm C and expanded cohort C with recurrent GBM: Prior treatment with bevacizumab for recurrent GBM, and secondary GBM; Allergies to temozolomide, decarbazine, IgG containing agents; Anti-cancer treatment 28 days prior to study Day 1.

发起方